

Teresa M Macdonald

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1964164/teresa-m-macdonald-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38
papers

188
citations

6
h-index

12
g-index

39
ext. papers

323
ext. citations

4.4
avg, IF

2.93
L-index

#	Paper	IF	Citations
38	Reduced growth velocity across the third trimester is associated with placental insufficiency in fetuses born at a normal birthweight: a prospective cohort study. <i>BMC Medicine</i> , 2017 , 15, 164	11.4	37
37	Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. <i>Nature Communications</i> , 2020 , 11, 2411	17.4	18
36	Shining light in dark corners: diagnosis and management of late-onset fetal growth restriction. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015 , 55, 3-10	1.7	15
35	Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study. <i>BMC Pregnancy and Childbirth</i> , 2018 , 18, 354	3.2	15
34	The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development. <i>Placenta</i> , 2019 , 84, 28-31	3.4	14
33	Cerebral-placental-uterine ratio as novel predictor of late fetal growth restriction: prospective cohort study. <i>Ultrasound in Obstetrics and Gynecology</i> , 2019 , 54, 367-375	5.8	12
32	Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia. <i>Placenta</i> , 2019 , 88, 1-7	3.4	6
31	Circulating adrenomedullin mRNA is decreased in women destined to develop term preeclampsia. <i>Pregnancy Hypertension</i> , 2019 , 16, 16-25	2.6	6
30	Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin. <i>Placenta</i> , 2020 , 91, 24-30	3.4	6
29	Blood-based biomarkers in the maternal circulation associated with fetal growth restriction. <i>Prenatal Diagnosis</i> , 2019 , 39, 947-957	3.2	6
28	Reduced growth velocity from the mid-trimester is associated with placental insufficiency in fetuses born at a normal birthweight. <i>BMC Medicine</i> , 2020 , 18, 395	11.4	6
27	Clinical tools and biomarkers to predict preeclampsia.. <i>EBioMedicine</i> , 2021 , 75, 103780	8.8	6
26	MicroRNAs 363 and 149 are differentially expressed in the maternal circulation preceding a diagnosis of preeclampsia. <i>Scientific Reports</i> , 2020 , 10, 18077	4.9	6
25	Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia. <i>Placenta</i> , 2021 , 105, 32-40	3.4	5
24	Circulating GATA2 mRNA is decreased among women destined to develop preeclampsia and may be of endothelial origin. <i>Scientific Reports</i> , 2019 , 9, 235	4.9	4
23	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth. <i>PLoS ONE</i> , 2020 , 15, e0238700	3.7	4
22	Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study. <i>Placenta</i> , 2021 , 110, 24-28	3.4	4

21	Prospective longitudinal assessment of the fetal left modified Myocardial Performance Index. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2019 , 32, 760-767	2	4
20	Circulating Growth Differentiation Factor 15 Is Increased Preceding Preeclampsia Diagnosis: Implications as a Disease Biomarker. <i>Journal of the American Heart Association</i> , 2021 , 10, e020302	6	4
19	Elevated Circulating and Placental SPINT2 Is Associated with Placental Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
18	Accelerated fetal growth velocity across the third trimester is associated with increased shoulder dystocia risk among fetuses who are not large-for-gestational-age: A prospective observational cohort study. <i>PLoS ONE</i> , 2021 , 16, e0258634	3.7	2
17	Estimation of neonatal body fat percentage predicts neonatal hypothermia better than birthweight centile.. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2022 , 1-8	2	1
16	A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeksVgestation in pregnancies destined to deliver small for gestational age infants. <i>Placenta</i> , 2021 , 117, 1-4	3.4	1
15	Pre-Clinical Investigation of Cardioprotective Beta-Blockers as a Therapeutic Strategy for Preeclampsia. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
14	Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. <i>Scientific Reports</i> , 2021 , 11, 16595	4.9	1
13	PSG7 and 9 (Pregnancy-Specific β Glycoproteins 7 and 9): Novel Biomarkers for Preeclampsia.. <i>Journal of the American Heart Association</i> , 2022 , e024536	6	1
12	Variable effect of maternal oral glucose load on circulating cell-free placental mRNAs. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2017 , 30, 501-503	2	0
11	Circulating Activin A is elevated at 36 weeksVgestation preceding a diagnosis of preeclampsia. <i>Pregnancy Hypertension</i> , 2021 , 27, 23-26	2.6	0
10	Circulating SPINT1 in the second trimester is reduced among pregnancies that ends in low birthweight neonates: cohort study of 2006 pregnancies.. <i>American Journal of Obstetrics & Gynecology MFM</i> , 2022 , 100618	7.4	0
9	Screening circulating proteins to identify biomarkers of fetal macrosomia. <i>BMC Research Notes</i> , 2019 , 12, 587	2.3	
8	Re. Shining light in dark corners: Diagnosis and management of late-onset fetal growth restriction. ANZJOG 2015; 55(1):3-10. Author response (I). <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015 , 55, 404-5	1.7	
7	Re. Shining light in dark corners: Diagnosis and management of late-onset fetal growth restriction. ANZJOG 2015; 55(1):3-10. Author response (II). <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 2015 , 55, 406-7	1.7	
6	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		
5	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		
4	Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth 2020 , 15, e0238700		

- 3 Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth **2020**, 15, e0238700
- 2 Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth **2020**, 15, e0238700
- 1 Appropriate-for-gestational-age infants who exhibit reduced antenatal growth velocity display postnatal catch-up growth **2020**, 15, e0238700